Parkinson DiseasePhase 4NCT03977441
the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease
A Phase 4 study testing Agomelatine or PIacebo in people with Parkinson Disease and Depression, run by Second Affiliated Hospital of Soochow University.
Trial summary
Among the patients with Parkinson's disease, about 40%~50% will suffer from depression, 40% will suffer from anxiety, and 40%~60% will suffer from sleep disorder. These non-motor symptoms of Parkinson's disease will cause great physical and psychological pain and affect the quality of life seriously. Read more about this study
- Who is it for?
- Ages 30 to 75 years
- Conditions the study is for
- Parkinson Disease, Depression, Sleep Disorders
- What is being tested?
- Agomelatine or PIacebo
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 240 participants
- Where
- No sites listed yet
- Study dates
- Jul 2019to Dec 2020
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosed as Parkinson's disease conforming to 2015 International Movement Disorder Society(MDS) diagnostic criteria
- Hoehn-Yahr ≤ 3 at "open" stage
- Mini-mental State Examination(MMSE) ≥ 24 points;
- Pittsburgh Sleep Quality Index (PSQI) > 7 points;
- HAMD-17 > 13 points
- Pramipexole hydrochloride tablets 0.75mg / d (0.25mg tid) has been used stably for one month
- Signed informed consent
Who cannot join
- Parkinson's syndrome and Parkinsonism-Plus syndrome
- Parkinson's movement symptoms are still fluctuating or the treatment of Parkinson's movement symptoms is unstable
- Hepatitis B virus carriers/patients, hepatitis C virus carriers/patients, patients with impaired liver function or elevated transaminase levels above the upper limit
- Other serious neurological diseases, mental illnesses and physical illnesses
- History of alcohol and drugs dependence
- Dementia
Show all 12Show fewer
- Combined treatment with CYP1A2 strong inhibitor (fluvoxamine, ciprofloxacin, rifampicin, amiodarone, mexiletine, atazanavir, etc.)
- High suicide risk or suicide attempt within 6 months (third item of HAMD-17 ≥ 3)
- Antidepressant medication or other psychiatric treatment in the past month
- pregnant or lactating
- intolerance or allergy to agomelatine active ingredients and excipients
- other conditions that are not suitable for the study considered by the investigators
Trial locations and contacts
No sites are listed yet.
About this study
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease
Among the patients with Parkinson's disease, about 40%~50% will suffer from depression, 40% will suffer from anxiety, and 40%~60% will suffer from sleep disorder. These non-motor symptoms of Parkinson's disease will cause great physical and psychological pain and affect the quality of life seriously. Commonly used therapeutic drugs, such as selective serotonin reuptake inhibitor (SSRI) and clonazepam, can cause a variety of side effects, including serotonin syndrome, sexual dysfunction, daytime fatigue, insomnia, residual effects and increased risk of falls. Therefore, a new and more reasonable therapeutic choice should be sought. Agomelatine is a new type of antidepressant with novel mechanism, and can improve sleep structure and circadian rhythm. The aim of this multi-center randomized controlled trial (RCT) is to clarify the role of agomelatine in improving sleep disorders and depression in patients with Parkinson's disease
- Being tested
- Agomelatine or PIacebo
- Medical subject headings
- Parkinson Disease, Depression, Sleep Wake Disorders, Chronobiology Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Agomelatine or PIaceboDrug
Also called Pramipexole
control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
| Study group | Role | What they receive |
|---|---|---|
| control group | Placebo comparator | treated with Pramipexole 0.75mg/d(0.25mg tid)+placebo 25mg qn *2weeks than Pramipexole 0.75mg/d(0.25mg tid)+placebo 50mg qn * 10 weeks Receives: Drug: Agomelatine or PIacebo |
| experimental group | Experimental | treated with Pramipexole 0.75mg/d(0.25mg tid)+Agomelatine25 mg qn *2weeks than Pramipexole 0.75mg/d(0.25mg tid)+Agomelatine 50mg qn * 10weeks Receives: Drug: Agomelatine or PIacebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
The efficacy of the treatment on the sleep disorders in Parkinson's disease evaluated by PSQI scale score change
The Pittsburgh sleep quality index (PSQI) is a widely used sleep evaluation scale in the Chinese population. The sensitivity and specificity of the PSQI (cut-off at 7) are 98.3% and 90.2%, respectively. PSQI has been used to evaluate the sleep disorders in patients with Parkinson's disease focusing on their sleep habits primarily.
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
Secondary outcomes (17)
The efficacy of the treatment on the sleep disorders in Parkinson's disease evaluated by PDSS, sleep diary and activity trackers
The Parkinson disease sleep scale (PDSS) is used to analyze the underlying causes of sleep disorders based on the results of each factor. In 2010, the International Movement Disorder Society (MDS) recommended that both PDSS and PSQI can be used for the screening and assessment of sleep disorders in the Parkinson's disease.
Sleep diary is an internationally recognized method to assist the examination of sleep disorders, and keeping recording a sleep diary every day is an effective therapy for some patients with insomnia.
Activity trackers can monitor and track fitness-related metrics such as distance walked or run, calorie consumption, heartbeat and quality of sleep, which can be used as a reference of patients' sleep quality and circadian rhythm.
Measured: PDSS:visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week); Sleep diary and activity trackers: 12 weeks, through study completion.
The efficacy on the excessive daytime sleepiness of patients with Parkinson's disease
Scale: Epworth sleepiness scale(ESS) score change The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'. The questionnaire takes no more than 2 or 3 minutes to answer.
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The efficacy on the fatigue of patients with Parkinson's disease
Scale:The Fatigue Severity Scale (FSS) score change The Fatigue Severity Scale (FSS) is a scale used in the evaluation of fatigue that affects patients. A list of statements/questions is provided. These statements are related to the different aspects of fatigue and how it affects the body. While rating the questions, one should make use of the scale with numbers from 1 to 7. If a person strongly agrees with a particular statement, the rating of 7 should be given. Strong disagreement is expressed by rating the question as 1. The sum total of ratings given to all questions is used to determine the degree or severity of fatigue that a person is suffering from. The total score of 36 or above calculated using the scale indicates that a person is suffering from fatigue-related health problem. A score that is lower than 36 shows that the health is normal.
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The efficacy on the circadian rhythm of patients with Parkinson's disease
Scale: The Morningness-Eveningness Questionnaire (MEQ) score change Circadian rhythm disorder is a kind of important sleep disorder. Body temperature and hormone level changes are effective methods to determine the daily cycle, but these methods are cumbersome. The scale evaluation is much easier to implement. The Morningness-Eveningness Questionnaire (MEQ) is the most widely known questionnaire to assess circadian preference. Cut-off points were evaluated: a range of 14-52 for Evening types, 53-64 for neither types, and 65-86 for Morning types.
Measured: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the rapid eye movement sleep behavior disorder (RBD) of patients with Parkinson's disease
Scale: The Rapid Eye Movement Sleep Behavior Disorder Questionnaire-Hong Kong (RBDQ-HK) score change It has been reported that the incidence of RBD in nucleoproteins disease is 90% for multiple system atrophy (MSA) and 38-56% for Parkinson's disease (PD). Therefore, the proportion and severity of RBD in the Parkinson's disease were needed to screened through the RBD screening questionnaire. The rapid eye movement sleep behavior disorder questionnaire (RBDQ)-Hong Kong was the first tool developed for quantifying the severity of RBD. The RBDQ-HK is a self-administered questionnaire with 13 questions. The RBDQ-HK score can range from 0 to 100. The sum total of ratings given to all questions is used to determine the degree or severity of RBD that a person is suffering from. The higher the RBDQ-HK score is, the worse the symptoms are.The best cut-off score was 17/18.
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The efficacy on the depression of patients with Parkinson's disease
Scales: The Hamilton Depression Scale-17 (HAMD-17) score change The Hamilton Depression Scale (HAMD) is a test measuring the severity of depressive symptoms in individuals, often those who have already been diagnosed as having a depressive disorder.In the 17-item version, nine of the items are scored on a five-point scale, ranging from 0 (not present) to 4 (severe). The remaining eight items are scored on a three-point scale, from 0 to 2, with zero representing absence of symptom, one indicating doubt that the symptom is present, and two representing clear presence of symptoms. Scores can range from 0 to 54. One formulation suggests that scores between 0 and 6 indicate a normal person with regard to depression, scores between 7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and scores over 24 indicate severe depression.
Measured: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the anxiety of patients with Parkinson's disease
Scales: The Hamilton Anxiety Scale(HAMA) score change
The Hamilton Anxiety Scale(HAMA) is a widely used interview scale to measure the severity of a patient's anxiety, based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview. The major value of HAM-A is to document the results of pharmaco- or psychotherapy, rather than as a diagnostic or screening tool. It takes 15-20 minutes to complete the interview and scoring. Each item is simply given a 5-point score: 0 (not present) to 4 (severe). The HAMA score can range from 0 to 56. The best cut-off score was 14.
Measured: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the movement of patients with Parkinson's disease
Scale: Unified Parkinson's Disease Rating Scale (UPDRS-III) score change The European Medicines Agency (EMA) guideline mentions the UPDRS II and III scales as accepted scales to measure the efficacy of a drug for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale-III (UPDRS-III) is the most widely used scale currently available for the clinical evaluation of motor dysfunction in Parkinson's disease (PD). Each item is simply given a 5-point score: 0 (Absent) to 4 (Marked in amplitude and present most of the time). The UPDRS-III score can range from 0 to 56. The higher the UPDRS-III score is, the worse the symptoms are.
Measured: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the life quality of patients with Parkinson's disease
Scale: Parkinson's Disease Questionnaire-8 (PDQ-8) score change Substantial evidence is available to suggest that the Parkinson's Disease Questionnaire (PDQ) is reliable, valid, responsive, acceptable and feasible as the tool for the assessment of quality of life in Parkinson's disease patients. For these reasons it has been widely adopted and generally considered the industry 'gold standard'. The PDQ is available in the 39-point PDQ-39 or the short form PDQ-8 (8 items). The PDQ-8 contains eight of the original 39 items of the PDQ-39; one item selected from each of the 8 scales.The PDQ-8 provides a reliable measure of overall health status and is ideal for studies in which a shorter questionnaire is preferred. Each item is simply given a 5-point score: 0 (Absent) to 4 (present most of the time). The PDQ-8 score can range from 0 to 32. The higher the PDQ-8 score is, the worse the symptoms are.
Measured: visit1(baseline),visit3(6th week),visit4(12th week)
Dosage and frequency of sedative and hypnotic drugs
Record the dosage and frequency of sedative and hypnotic drugs taken by the patients every visit and analyze the difference between two groups
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the total number of red blood cells.
The total number of red blood cells will be monitored through the blood routine examination to see whether the number will change abnormally.
Normal range of the total number of red blood cells is 4.0-5.50*10^12/L (male) and 3.5~5.0*10^12/L (female) (reference value range)
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the total number of white blood cells.
The total number of white blood cells will be monitored through the blood routine examination to see whether the number will change abnormally.
Normal range of the total number of white blood cells is 4-10*10^9/L (male) and 4-10*10^9/L (female) (reference value range)
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the platelet count.
The platelet count will be monitored through the blood routine examination to see whether the number will change abnormally.
Normal range of the platelet count is 100-300*10^9/L (male) and 100-300*10^9/L (female) (reference value range)
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the concentration of the hemoglobin.
The concentration of the hemoglobin will be monitored through the blood routine examination to see whether it will change abnormally.
Normal range of the concentration of the hemoglobin is 120-160*g/L (male) and 110-150*g/L (female) (reference value range)
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the liver function
the liver function will be monitored through the examination of the alanine aminotransferase (ALT) and the aspartate aminotransferase (AST) in the biochemical routine examination Normal range of the concentration of the ALT is 0~40U/L (reference value range) Normal range of the concentration of the AST is 0~40U/L (reference value range)
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the renal function
the renal function will be monitored through the examination of the creatinine (Cr) and the urea nitrogen (BUN) in the biochemical routine examination Normal range of the concentration of the Cr is 53~106umol/L (male) and 44~97umol/L (female) (reference value range) Normal range of the concentration of the BUN is 2.86-7.14mmol/L(reference value range)
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
Adverse Event and Serious Adverse Event
Safety index
Measured: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2019
- Study startJul 2019 (estimated)
- Primary completionDec 2020 (estimated)
- Study completionDec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- treatment group: treated with agomelatine control group: treated with placebo
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital of Soochow University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chun-Feng Liu, Second Affiliated Hospital of Soochow University
- Investigators
- Chun-Feng Liu, MD, Principal investigator, Second Affiliated Hospital of Soochow University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03977441
- Sponsor's protocol ID
- JD-LK-2019-008-02
- Status last verified
- Jun 2019
- First submitted
- 12 May 2019
- Last updated
- 6 Jun 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: There is a plan to make individual participant data (IPD) available to the other researchers, who participant in the study, since this is a muti-center study. The study protocol, statistical Analysis Plan (SAP), informed Consent Form (ICF), clinical Study Report (CSR) will be shared. And all the data collected by the single center will be reported back.
Publications
Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol. 2012 May;11(5):429-42. doi: 10.1016/S1474-4422(12)70049-2.
PubMed 22516078Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):183-9; quiz 313. doi: 10.1002/mds.21803.
PubMed 17987654Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235-45. doi: 10.1016/S1474-4422(06)70373-8.
PubMed 16488379Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May;8(5):464-74. doi: 10.1016/S1474-4422(09)70068-7.
PubMed 19375664Yong MH, Fook-Chong S, Pavanni R, Lim LL, Tan EK. Case control polysomnographic studies of sleep disorders in Parkinson's disease. PLoS One. 2011;6(7):e22511. doi: 10.1371/journal.pone.0022511. Epub 2011 Jul 22.
PubMed 21799880Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Mar 16;74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.
PubMed 20231670Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res Clin Exp. 2005 Mar;66(2):96-106. doi: 10.1016/j.curtheres.2005.04.006.
PubMed 24672116Lam RW. Addressing circadian rhythm disturbances in depressed patients. J Psychopharmacol. 2008 Sep;22(7 Suppl):13-8. doi: 10.1177/0269881108092591.
PubMed 18753278Hogl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15;25(16):2704-16. doi: 10.1002/mds.23190.
PubMed 20931631Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, Lacroix AZ, Landis CA, Woods NF, Freeman EW. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause. 2012 Aug;19(8):848-55. doi: 10.1097/gme.0b013e3182476099.
PubMed 22433978Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92. doi: 10.1002/mds.21333.
PubMed 17394234Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord. 2000 Nov;15(6):1221-4. doi: 10.1002/1531-8257(200011)15:63.0.co;2-h.
PubMed 11104209Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.
PubMed 22496199Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X. Epub 2010 May 7.
PubMed 20452823San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008 Sep;23(6):396-402. doi: 10.1016/j.eurpsy.2008.04.002. Epub 2008 Jun 25.
PubMed 18583104
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT03977441
- Acronym / sponsor ID
- JD-LK-2019-008-02
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital of Soochow UniversityUniversity, hospital or other
- Study start
- Jul 2019 (estimated)
- Primary completion
- Dec 2020 (estimated)
- Study completion
- Dec 2020 (estimated)
- First posted
- 6 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Among the patients with Parkinson's disease, about 40%~50% will suffer from depression, 40% will suffer from anxiety, and 40%~60% will suffer from sleep disorder. These non-motor symptoms of Parkinson's disease will cause great physical and psychological pain and affect the quality of life seriously. Commonly used therapeutic drugs, such as selective serotonin reuptake inhibitor (SSRI) and clonazepam, can cause a variety of side effects, including serotonin syndrome, sexual dysfunction, daytime fatigue, insomnia, residual effects and increased risk of falls. Therefore, a new and more reasonable therapeutic choice should be sought. Agomelatine is a new type of antidepressant with novel mechanism, and can improve sleep structure and circadian rhythm. The aim of this multi-center randomized controlled trial (RCT) is to clarify the role of agomelatine in improving sleep disorders and depression in patients with Parkinson's disease
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- treatment group: treated with agomelatine control group: treated with placebo
| Arm | Type | Receives |
|---|---|---|
| control group | Placebo comparator | Drug: Agomelatine or PIacebotreated with Pramipexole 0.75mg/d(0.25mg tid)+placebo 25mg qn *2weeks than Pramipexole 0.75mg/d(0.25mg tid)+placebo 50mg qn * 10 weeks |
| experimental group | Experimental | Drug: Agomelatine or PIacebotreated with Pramipexole 0.75mg/d(0.25mg tid)+Agomelatine25 mg qn *2weeks than Pramipexole 0.75mg/d(0.25mg tid)+Agomelatine 50mg qn * 10weeks |
Who may qualify
- Ages
- 30 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- diagnosed as Parkinson's disease conforming to 2015 International Movement Disorder Society(MDS) diagnostic criteria
- Hoehn-Yahr ≤ 3 at "open" stage
- Mini-mental State Examination(MMSE) ≥ 24 points;
- Pittsburgh Sleep Quality Index (PSQI) > 7 points;
- HAMD-17 > 13 points
Key exclusion criteria (12 listed)
- Parkinson's syndrome and Parkinsonism-Plus syndrome
- Parkinson's movement symptoms are still fluctuating or the treatment of Parkinson's movement symptoms is unstable
- Hepatitis B virus carriers/patients, hepatitis C virus carriers/patients, patients with impaired liver function or elevated transaminase levels above the upper limit
- Other serious neurological diseases, mental illnesses and physical illnesses
- History of alcohol and drugs dependence
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Agomelatine or PIaceboAlso: Pramipexolecontrol group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine | Drug | control group, experimental group |
Primary outcome
The efficacy of the treatment on the sleep disorders in Parkinson's disease evaluated by PSQI scale score change
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Pittsburgh sleep quality index (PSQI) is a widely used sleep evaluation scale in the Chinese population. The sensitivity and specificity of the PSQI (cut-off at 7) are 98.3% and 90.2%, respectively. PSQI has been used to evaluate the sleep disorders in patients with Parkinson's disease focusing on their sleep habits primarily.
17 secondary outcomes
The efficacy of the treatment on the sleep disorders in Parkinson's disease evaluated by PDSS, sleep diary and activity trackers
Time frame: PDSS:visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week); Sleep diary and activity trackers: 12 weeks, through study completion.
The efficacy on the excessive daytime sleepiness of patients with Parkinson's disease
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The efficacy on the fatigue of patients with Parkinson's disease
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The efficacy on the circadian rhythm of patients with Parkinson's disease
Time frame: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the rapid eye movement sleep behavior disorder (RBD) of patients with Parkinson's disease
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The efficacy on the depression of patients with Parkinson's disease
Time frame: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the anxiety of patients with Parkinson's disease
Time frame: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the movement of patients with Parkinson's disease
Time frame: visit1(baseline),visit3(6th week),visit4(12th week)
The efficacy on the life quality of patients with Parkinson's disease
Time frame: visit1(baseline),visit3(6th week),visit4(12th week)
Dosage and frequency of sedative and hypnotic drugs
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the total number of red blood cells.
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the total number of white blood cells.
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the platelet count.
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the concentration of the hemoglobin.
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the liver function
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
The Safety of Agomelatine in the Patients With Parkinson's Disease - the effect on the renal function
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
Adverse Event and Serious Adverse Event
Time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2019.
- Background: PubMed 22516078Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol. 2012 May;11(5):429-42. doi: 10.1016/S1474-4422(12)70049-2.
- Background: PubMed 17987654Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):183-9; quiz 313. doi: 10.1002/mds.21803.
- Background: PubMed 16488379Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235-45. doi: 10.1016/S1474-4422(06)70373-8.
- Background: PubMed 19375664Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May;8(5):464-74. doi: 10.1016/S1474-4422(09)70068-7.
- Background: PubMed 21799880Yong MH, Fook-Chong S, Pavanni R, Lim LL, Tan EK. Case control polysomnographic studies of sleep disorders in Parkinson's disease. PLoS One. 2011;6(7):e22511. doi: 10.1371/journal.pone.0022511. Epub 2011 Jul 22.
- Background: PubMed 20231670Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Mar 16;74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.
- Background: PubMed 24672116Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res Clin Exp. 2005 Mar;66(2):96-106. doi: 10.1016/j.curtheres.2005.04.006.
- Background: PubMed 18753278Lam RW. Addressing circadian rhythm disturbances in depressed patients. J Psychopharmacol. 2008 Sep;22(7 Suppl):13-8. doi: 10.1177/0269881108092591.
- Background: PubMed 20931631Hogl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15;25(16):2704-16. doi: 10.1002/mds.23190.
- Background: PubMed 22433978Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, Lacroix AZ, Landis CA, Woods NF, Freeman EW. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause. 2012 Aug;19(8):848-55. doi: 10.1097/gme.0b013e3182476099.
- Background: PubMed 17394234Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92. doi: 10.1002/mds.21333.
- Background: PubMed 11104209Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord. 2000 Nov;15(6):1221-4. doi: 10.1002/1531-8257(200011)15:63.0.co;2-h.
- Individual participant dataSharing planned: Yes. There is a plan to make individual participant data (IPD) available to the other researchers, who participant in the study, since this is a muti-center study. The study protocol, statistical Analysis Plan (SAP), informed Consent Form (ICF), clinical Study Report (CSR) will be shared. And all the data collected by the single center will be reported back.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chun-Feng Liu, MD principal investigator
Second Affiliated Hospital of Soochow University
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Agomelatine or PIacebo in people with Parkinson Disease and Depression, run by Second Affiliated Hospital of Soochow University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chun-Feng Liu, MD (+86 512 67783307, liucf@suda.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The efficacy of the treatment on the sleep disorders in Parkinson's disease evaluated by PSQI scale score change (time frame: visit1(baseline),visit2(2ed week),visit3(6th week),visit4(12th week)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03977441, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2019.